Pharmacomechanical Catheter-Directed Thrombolysis With the Bashir Endovascular Catheter for Acute Pulmonary Embolism: The RESCUE Study

• Published in: JACC. Cardiovascular interventions 2022-12, Vol.15 (23), p.2427-2436
• Main Authors: Bashir, Riyaz, Foster, Malcolm, Iskander, Ayman, Darki, Amir, Jaber, Wissam, Rali, Parth M, Lakhter, Vladimir, Gandhi, Ripal, Klein, Andrew, Bhatheja, Rohit, Ross, Charles, Natarajan, Kannan, Nanjundappa, Aravinda, Angle, John F, Ouriel, Kenneth, Amoroso, Nancy E, Firth, Brian G, Comerota, Anthony J, Piazza, Gregory, Rosenfield, Kenneth, Sista, Akhilesh K
• Format: Article
• Language: English
• Subjects: Hemorrhage - chemically induced; Humans; Pulmonary Embolism - diagnostic imaging; Pulmonary Embolism - therapy; Tissue Plasminogen Activator - adverse effects; Treatment Outcome
• ISSN: 1876-7605
• DOI: 10.1016/j.jcin.2022.09.011

Catheter-directed thrombolysis (CDT) has been associated with rapid recovery of right ventricular (RV) function. The Bashir catheter was developed for enhanced thrombolysis in large vessels such as the pulmonary arteries (PAs) with lower doses of tissue plasminogen activator (tPA). The aim of this study was to evaluate the efficacy and safety of tPA infused using a pharmacomechanical (PM) CDT device called the Bashir endovascular catheter in patients with intermediate-risk acute pulmonary embolism (PE). Patients with symptoms of acute PE with computed tomographic evidence of RV dilatation were enrolled. The Bashir catheter was used to deliver 7 mg tPA into each PA over 5 hours. The primary efficacy endpoint was the core laboratory-assessed change in computed tomographic angiography-derived RV/left ventricular (LV) diameter ratio at 48 hours, and the primary safety endpoint was serious adverse events (SAEs) including major bleeding at 72 hours. At 18 U.S. sites, 109 patients were enrolled. The median device placement time was 15 minutes. At 48 hours after PM-CDT, the RV/LV diameter ratio decreased by 0.56 (33.3%; P < 0.0001). PA obstruction as measured by the refined modified Miller index was reduced by 35.9% (P < 0.0001). One patient (0.92%) had 2 SAEs: a retroperitoneal bleed (procedure related) and iliac vein thrombosis (device related). Two other procedure-related SAEs were epistaxis and non-access site hematoma with anemia. PM-CDT with the Bashir endovascular catheter is associated with a significant reduction in RV/LV diameter ratio and a very low rate of adverse events or major bleeding in patients with intermediate-risk acute PE. The notable finding was a significant reduction in PA obstruction with low-dose tPA. (Recombinant tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden [RESCUE]; NCT04248868).